535 results on '"Fridman, Wolf H."'
Search Results
52. Supplementary Figure 2 from The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer
53. Supplementary Figure Legends 1-5 from The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer
54. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
55. Toward Genetic Dissection of High and Low Antibody Responsiveness in Biozzi Mice
56. Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
57. Concluding Remarks
58. “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015
59. Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control
60. Abstract PR002: Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS)
61. Abstract IA007: B cell immunity generation in tertiary lymphoid structures, a major determinant of sarcoma immune response to immunotherapy
62. Spatial transcriptomics
63. The immune contexture in cancer prognosis and treatment
64. Les structures lymphoïdes tertiaires génèrent et propagent des plasmocytes produisant des anticorps antitumoraux dans le cancer du rein
65. SHIP1-mediated negative regulation of cell activation and proliferation by FcγRIIB
66. The immune response in cancer: from immunology to pathology to immunotherapy
67. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
68. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers
69. Transcriptomic analysis reveals novel tumour microenvironment subtypes in IDH wildtype glioblastoma
70. ISY14-5 - Integration of molecular and immune classifications to guide cancer immunotherapies
71. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
72. B cells and cancer
73. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome
74. Cross-Linking of IgG Receptors Inhibits Membrane Immunoglobulin-Stimulated Calcium Influx in B Lymphocytes
75. Isotype Regulation of Antibody Production: T-Cell Hybrids Can be Selectively Induced to Produce IgG1 and IgG2 Subclass-Specific Suppressive Immunoglobulin-Binding Factors
76. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
77. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
78. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma
79. Additional file 1 of The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression
80. webMCP-counter: a web interface for transcriptomics-based quantification of immune and stromal cells in heterogeneous human or murine samples
81. TAMI-51. IDENTIFYING NEW TUMOR MICROENVIRONMENT (TME) CONTEXTS OF VULNERABILITY IN GLIOBLASTOMA
82. The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on Chromosome 8p12
83. Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control
84. Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules
85. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
86. The tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends
87. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression
88. B cells are associated with survival and immunotherapy response in sarcoma
89. Therapeutic Targeting of the Colorectal Tumor Stroma
90. Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
91. BETTER UNDERSTANDING TUMOR–HOST INTERACTION IN HEAD AND NECK CANCER TO IMPROVE THE DESIGN AND DEVELOPMENT OF IMMUNOTHERAPEUTIC STRATEGIES
92. Identification of two quantitative trait loci involved in antibody production on mouse chromosome 8
93. Tumor Necrosis Factor-α- and IL-4-Independent Development of Langerhans Cell-Like Dendritic Cells from M-CSF-Conditioned Precursors
94. Immunoreceptor Tyrosine-based Inhibition Motif-dependent Negative Regulation of Mast Cell Activation and Proliferation
95. In vitro inhibition of tumor B cell growth by IgG-BF-producing FcγRII+T cell hybridoma and by immunoglobulin G-binding factors
96. Murine soluble Fcγ receptors/IgG-binding factors (IgG-BF): Analysis of the relation to FcγRII and production of milligram quantities of biologically active recombinant IgG-BF
97. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization
98. Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells
99. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2
100. Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.